- Home
- / BRIM Biotechnology
BRIM Biotechnology
Stock Price
NT$43.8
2024-10-29
Market Capitalization
NT$5 B
2024-10-29
Revenue
NT$5.5 M
FY, 2025
BRIM Biotechnology Summary
Company Summary
- Overview
- BRIM Biotechnology (全福生物科技股份有限公司) is a company that develops drugs for oncology and infectious disease. It offers treatment for dry eye syndrome (DES) which treats and repairs corneal damage, a drug for osteoarthritis.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Taipei, TW | view all locations
- Website
- https://www.brimbiotech.com
- Cybersecurity rating
Table of Contents
Key People
Frank Lee, Director and Chief Strategic Officer
Operating MetricsView all
Trademarks
2
Jun, 2023
Awards
4
Jun, 2023
LocationsView all
1 location detected
Taipei, Taipei City HQ
Taiwan
8f, No. 1, Alley 30, Lane 358, Ruiguang Rd
BRIM Biotechnology Financials
Summary Financials
- Revenue (FY, 2025)
- NT$5.5M
- Gross profit (FY, 2025)
- NT$1.3M
- Net income (FY, 2025)
- (NT$450.9M)
- Cash (FY, 2025)
- NT$798.4M
- EBIT (FY, 2025)
- (NT$466.5M)
- Enterprise value
- $4.3B